Development and manufacturing services available
Lonza Biologics Guangzhou is a multiproduct facility for clinical and commercial supply. The site capabilities include single-use bioreactors at 200L, 1,000L and 2,000L and downstream processing equipment. The site will employ Lonza’s current GS Xceed® platform technology. The facility is capable of producing mammalian cell culture therapeutic proteins including monoclonal antibodies, bispecific antibodies, fusion proteins and recombinant enzymes leveraging our global network support.
Our Quality systems and regulatory inspections
Lonza’s global quality system has consistently demonstrated compliance with major global regulators i.e. FDA, EMA, PMDA, ANVISA, TGA. It will also meet China NMPA requirement.
The same rigorous quality management systems, documentation practices, training and oversight will be applied to the Lonza Biologics Guangzhou facility to ensure one global quality standard.